F18.27
Inhalant dependence with inhalant-induced dementia
Clinical Classification Guidelines
Inclusion Terms
- Inhalant use disorder, moderate, with inhalant induced major neurocognitive disorder
- Inhalant use disorder, severe, with inhalant induced major neurocognitive disorder
Medical Intelligence & Overview
Inhalant dependence with inhalant-induced dementia is a serious condition that involves the compulsive use of inhalant substances alongside a significant decline in mental functions caused by inhalant use. This condition falls under the category of inhalant use disorder, which can range from moderate to severe, and results in major neurocognitive disorder, affecting memory, thinking, and daily functioning. Recognizing the signs and understanding the nature of this disorder is crucial for seeking appropriate help and support.
Causes & Symptoms
Clinical Causes: Repeated, prolonged use of inhalant substances such as solvents, aerosols, gases, or nitrates. Substance dependence developing due to genetic predisposition or environmental factors. Psychological factors like stress, depression, or peer pressure influencing inhalant use. Availability and accessibility of inhalant products in certain environments. Lack of awareness about the health risks associated with inhalant use.
Key Symptoms: Persistent cravings or strong desire to use inhalants. Increased tolerance, requiring higher amounts to achieve the same effect. Withdrawal symptoms such as irritability, nausea, or sweating when not using inhalants. Cognitive impairments including memory loss, difficulty concentrating, and confusion. Problems with judgment, decision-making, and problem-solving skills. Changes in behavior, including social withdrawal or neglect of personal responsibilities. Physical symptoms such as dizziness, muscle weakness, or tremors. In advanced stages, signs of major neurocognitive disorder affecting daily life.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a thorough medical and psychological assessment, including a detailed history of inhalant use and cognitive evaluation. Healthcare professionals may utilize neuropsychological tests, physical examinations, and brain imaging studies to assess the extent of cognitive decline and confirm inhalant dependence. Diagnostic criteria from mental health guidelines help determine the severity and impact of the disorder.
Treatment Protocols: Detoxification programs to safely manage withdrawal symptoms. Cognitive-behavioral therapy (CBT) to address dependence behaviors and develop coping skills. Group therapy and peer support groups to promote recovery and provide social support. Rehabilitation programs targeting cognitive deficits and functional improvement. Medication may be considered to manage symptoms or co-occurring mental health conditions, under professional guidance. Long-term monitoring and follow-up to prevent relapse and support cognitive health.
Clinical Advice & FAQs
Billing Guidance
Is F18.27 a billable ICD-10 code?
Yes, F18.27 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F18.27?
Clinical documentation must specify the nature of Inhalant dependence with inhalant-induced dementia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference